BridgeBio Pharma, Inc. (BBIO) vs Halozyme Therapeutics, Inc. (HALO)

BridgeBio Pharma, Inc. and Halozyme Therapeutics, Inc. are both Biotechnology companies. BridgeBio Pharma, Inc. and Halozyme Therapeutics, Inc. are of similar size ($13.1B and $13.1B). BridgeBio Pharma, Inc. has negative trailing earnings, so its P/E is not meaningful; Halozyme Therapeutics, Inc. trades at 32.4×. BridgeBio Pharma, Inc. grew revenue faster over the last twelve months: 202.4% against 41.2%. Halozyme Therapeutics, Inc. has the higher net margin (24.9% vs −97.0%) and the higher return on invested capital (18.1% vs 0.00%). Across the 18 metrics below, Halozyme Therapeutics, Inc. leads on 13 and BridgeBio Pharma, Inc. on 5.